|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 每日1次利拉鲁肽与每日2次艾塞那肽治疗2型糖尿病比较:一项为期26周的随机、平行组、多国开放标记试验(LEAD-6)显示文摘背景与大多数抗高血糖药物不同,胰高血糖素样肽-1(GLP-1)受体激动剂的药理作用依赖于葡萄糖水平,并且有助于减轻患者体重。本研究比较了利拉鲁肽(一种人GLP-1类似物)与艾塞那肽(一种基于醋酸艾塞那肽的GLP-1受体激动剂)治疗2型糖尿病的疗效和安全性。方法对于用最大耐受剂量二甲双胍或(和)磺脲仍控制不良的2型糖尿病成年患者,根据之前服用的抗糖尿病药物进行分层,并随机分配这些患者额外接受利拉鲁肽1.8mg每El1次(n=233)或艾塞那肽10μg每日2次(n=231),进行为期26周的开放标记、平行组、多国(15个国家)研究。主要终点是糖化血红蛋白(HbA1c)水平的变化,疗效分析采用意向性治疗分析。本试验在Clinical Trial.gov注册,注册号为NCT00518882。结果受试者的HbA1c平均基线水平为8.2%。与艾塞那肽相比,利拉鲁肽能显著降低HbA1c平均水平[-1.12%(s=0.08%)vs-0.79%(s=0.08%);疗效差异估计值为-0.33%,95%CI-0.47%~-0.18%;P〈0.0001],并且利拉鲁肽组有更多患者HbA1c水平低于7%(54%vs543%;OR 2.02,95%CI 1.31~3.11;P=0.0015)。利拉鲁肽降低平均空腹血糖的能力也显著优于艾塞那肽[-1.61mmol/Lb=0.20)vs-0.60mmol/L(s=0.20);疗效差异估计值为-1.01mmol/L,95%CI-1.37—-0.65;P〈0.0001],但是其降低早餐和晚餐后血糖的能力较艾塞那肽差。两种药物促进患者体重减轻的作用相似(利拉鲁肽组~3.24kg vs艾塞那肽组-2.87地)。耐受性均较好,但与艾塞那肽组相比,利拉鲁肽组患者恶心的持续时间较短(估计的治疗相关事件率比值为0.448,P〈0.0001),轻度低血糖的发生率也较低(每患者每年的事件发生数为1.93vs2.60;发生率比值为0.55,95%C10.34~0.88:P=0.0131;轻度低血糖的发生率为25.5%掷33.6%)。2例同时注射艾塞那肽和一种磺脲类药物的患者发生了严重的低血糖。结论相对于艾塞那肽每日2次,利拉鲁肽每日1次能显著改善血糖控制水平,且患者的耐受性更好。研究结果提示利拉鲁肽或许是2型糖尿病的一种治疗选择,特别是在减轻体重和低血糖风险作为主要考虑因素的情况下。 | John B Buse Julia Rosenstock Giorgio Sesti Wolfgang E Schmidt Eduard Montanya Jason H Brett Marcin Zychma Lawrence Blonde 赵乐(译) | 2009 | 世界临床医学2009，，11： | 3 |
| 2 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)显示文摘 | John B Buse Julio Rosenstock Giorgio Sesti Wolfgang E Schmidt Eduard Montanya Jason H Brett Marcin Zychma Lawrence Blonde | 2009 | The Lancet2009，，9683： | 2 |
| 3 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)显示文摘 | John B Buse Julio Rosenstock Giorgio Sesti Wolfgang E Schmidt Eduard Montanya Jason H Brett Marcin Zychma Lawrence Blonde | 2009 | The Lancet . 2009 (9683)2009，，9683： | 1 |
| 4 | Cytokine-facilitated priming of CD8+ T cell responses by DNA vaccination显示文摘 | Marcin K Andrea K Hansjrg H | 2003 | J Molecul Med2003，81，2： | 1 |
| 5 | Effects of substituting a OH group bya F atomin D glucose: Ab initio and DFT Analysis 显示文摘 | MARCIN H JACEK R | 2001 | J AmChem Soc2001，123，10： | 1 |
| 6 | The new method of fabri- cation of submicron structures by optical lithography with mask shifting and mask rotation 显示文摘 | I Kornelia H Marcin P Bogdan | 2013 | Central European Journal of Physics2013，11，2： | 1 |
| 7 | Chitin and chitosan: Part II, Applications of chitosan显示文摘 | Struszczyk Marcin H | 2002 | Polym2002，47，6： | 1 |
| 8 | Fluidized bed gasification as a mature and reliable technology for the production of bio-syngas and applied in the production of liquid transportation fuels-A review显示文摘 | Marcin Siedlecki Wiebren de Jong Adrian H M Verkooijen | 2011 | Energies2011，4，： | 1 |
| 9 | The effects of cold acclimation on photosynthetic apparatus and the expression of COR14b in four genotypes of harley (Hordeum vulgare) contrasting in their tolerance to freezing and high-light treatment in cold eondi- tions显示文摘 | MARCIN R BARBARA W KATARZYNA H | 2008 | Annals of Botany2008，101，： | 1 |
| 10 | Mechanical behaviour of C45 grade steel deformed in semi-solid state 显示文摘 | MARCIN H MIROSLAW G | 2011 | Procedia Engineering2011，10，： | 1 |
| 11 | Semi-device independent ran-dom number expansion protocol with n to I quantum random accesscodes显示文摘 | Li H W Marcin P Yin Z Q | 2012 | Phys Rev A2012，85，5： | 1 |
| 12 | The Influence of Direct Non-Thermal Plasma Treatment on Particulate Matter (PM) and NOx in the Exhaust of Marine Diesel Engines 显示文摘 | MARCIN H STANISLAW K BORKOWSKI T | 2010 | Polish Journal of Environ- mental Studies2010，19，6： | 1 |
| 13 | Cytokine-facilitated priming of CD8 + T cell responses by DNA vaccination显示文摘 | Marcin K Andrea K Hansjorg H et al | 2003 | J Mol Med2003，81，2： | 1 |
| 14 | 不伴有视网膜静脉阻塞的猪眼作放射状视神经切开显示文摘目的:证实猪眼在放射状视神经切开(RON)后无静脉阻塞发生时的组织病理学改变。 | Marcin P. Czajka Thomas J. Cummings Brooks W. McCuen H Cynthia A. Toth Hoang Nguyen Sharon Fekrat 陆遥(译) | 2005 | 美国医学会眼科杂志(中文版)2005，17，2： | 0 |
| 15 | Pancreatic cancer risk variant ABO rs505922 in patients with cholangiocarcinoma显示文摘The aim of this study was to investigate an association between the development of cholangiocarcinoma(CCA)and the ABO variant rs505922(known to increase pan-creatic cancer risk)in a large cohort of European individuals with CCA.In total,180 individuals with CCA and 350 CCA-free controls were included.The ABO variant rs505922 was genotyped using a polymerase chain reaction-based assay.Association between this single nucleotide polymorphism(SNP)and CCA was tested in contingency tables.Neither allele distributions nor association tests and regression analysis provided evidence for an increased risk of CCA among carriers of the ABO variant(all P > 0.05).Nevertheless,we documented a deviation from Hardy-Weinberg equilibrium in the entire CCA cohort(P = 0.028)and for patients with intrahe-patic(P = 0.037)but not extrahepatic tumor localization(P > 0.05).The association tests did not provide evidence for a prominent role of the investigated SNP in the genetic risk of CCA.However,Hardy-Weinberg disequilibrium in the entire cohort and the intrahepatic CCA subgroup warrants future studies investigating a potential CCA risk modulation by individual blood groups. | Marcin Krawczyk Florentina Mihalache Aksana Hblinger Monica Acalovschi Frank Lammert Vincent Zimmer | 2011 | World Journal of Gastroenterology2011，17，41： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员